HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ZUMA-7 trial shows the value of axicabtagene ciloleucel for early relapsed B-cell lymphoma.

AuthorsMary Beth Nierengarten
JournalCancer (Cancer) Vol. 129 Issue 19 Pg. 2926 (10 01 2023) ISSN: 1097-0142 [Electronic] United States
PMID37656154 (Publication Type: News)
Chemical References
  • axicabtagene ciloleucel
  • Biological Products
Topics
  • Humans
  • Biological Products (therapeutic use)
  • Lymphoma, B-Cell (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: